The matrix metalloproteinases and their inhibitors in pancreatic cancer

International Journal of Pancreatology

Volumn 21, Issue 1, 1997, Pages 1-12

  Bramhall, Simon R ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

BB2516; BB94; Matrix metalloproteinase; pancreatic cancer; treatment

Indexed keywords

BATIMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE;

ANTINEOPLASTIC ACTIVITY; CANCER INVASION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW;

GELATINASES; GLYCOPROTEINS; HUMANS; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; PANCREATIC NEOPLASMS; PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 65749308863     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Nagakawa T, Konishi I, Higashino Y, Ueno K, Ohta T, Kayahara M, Ueda N, Macda K, Miyazaki I. The spread and prognosis of carcinoma in the region of the pancreatic head. Jpn J Surg 1989; 19(5): 510-518.
2. Nagakawa T, Kayahara M, Ueno K, Ohta T, Konishi I, Ueda N, Miyazaki I. A clinicopathologic study on neural invasion in cancer of the pancreatic head. Cancer 1992; 69(4): 930-935.
3. Mollenhauer J, Roether I, Kern HF. Distribution of extra-cellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro. Pancreas 1987; 2(1): 14-24.
4. Hart IR, Goode NT, Wilson RE. Molecular aspects of the metastatic cascade. Biochim Biophvs Acta 1989; 989: 65-84.
5. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67,68.
6. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51(Suppl): 5054s-5059s.
7. Martinez-Hernandez A, Amenta PS. The basement membrane in pathology. Lab Invest 1983; 48(6): 656-677.
8. Forster SJ, Talbot IC, Clayton DG, Critchley DR. Tumour basement membrane laminin in adenocarcinoma of rectum: an immunohistochemical study of biological and clinical significance. Int J Cancer 1986; 37: 813-817.
9. Charpin C, Lissitzky JC, Jacquemier J, Lavaut MN, Kopp F, Pourreau-Schneider N, Martin PM, Toga M. Immunohistochemical detection of laminin in 98 human breast carcinomas: a light and electron microscopic study. Hum Pathol 1986; 17(4): 355-365.
10. Lee CS, Montebello J, Georgiou T, Rode J. Distribution of type IV collagen in pancreatic adenocarcinoma and chronic pancreatitis. Int J Exp Pathol 1994; 75: 79-83.
11. Wang Z-h, Manabe T, Ohshio G, Imamura T, Yoshimura T, Suwa H, Ishigami S, Kyogoku T. Immunohistochemical study of heparan sulfate proteoglycan in adenocarcinomas of the pancreas. Pancreas 1994; 9(6): 758-763.
12. Cottam DW, Rees RC. Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis (review). Int J Oncol 1993; 2: 861-872.
13. Docherty AJ, Murphy G. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann Rheum Dis 1990; 49(1): 469-479.
14. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370(6484): 61-65.
15. Will H, Hinzman B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995; 231: 602-608.
16. Takino T, Sato H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. J Biol Chem 1995; 270(39): 23,013-23,020.
17. McCroskery PA, Richards JF, Harris ED. Purification and characterisation of a collagenase extracted from rabbit tumours. Biochem J 1975; 152: 131-142.
18. Nethery A, O'Grady RL. Identification of a metalloproteinase co-purifying with rat tumour collagenase and the characteristics of fragments of both enzymes. Biochim Biophys Acta 1989; 994(2): 149-160.
19. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet 1990; 6(4): 121-125.
20. Pei D, Majmudar G, Weiss SJ. Hydrolytic activation of a breast carcinoma-cell derived serpin by human stromelysin-3. J Biol Chem 1994; 269: 25,849-25,855.
21. Yamagata S, Ito Y, Tanaka R, Shimizu S. Gelatinases of metastatic cell lines of murine colonic carcinoma as detected by substrate-gel electrophoresis. Biochem Biophys Res Commun 1988; 151(1): 158-162.
22. Yamagata S, Tanaka R, Ito Y, Shimizu S. Gelatinases of murine metastatic tumour cells. Biochem Biophys Res Commun 1989; 158(1): 228-234.
23. r.92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 1990; 50(13): 3872-3877.
24. Van-Der-Stappen JWJ, Hendriks T, Wobbes T. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer 1990; 45: 1071-1078.
25. Wirl G, Frick J. Collagenase-A marker enzyme in human bladder cancer? Urol Res 1979; 7: 103-108.
26. Matrisian LM, Bowden GT. Stromelysin/transin and tumor progression. Semin Cancer Biol 1990; 1(2): 107-115.
27. Matrisian LM, McDonnell S, Miller DB, Navre M, Seftor EA, Hendrix MJC. The role of the matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas. Am J Med Sci 1991; 302(3): 157-162.
28. Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA. Evaluation of basement membrane components and the 12 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 1992; 16(5): 500-507.
29. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE, Turner DE. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991; 49: 666-672.
30. Waxman J, Wasan H. The architecture of cancer. Br Med J 1992; 305: 1306,1307.
31. Polette M, Clavel C, Birembaut P, De-Clerck YA. Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathol Res Pract 1993; 189(9): 1052-1057.
32. Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G, Rouyer N, Rio MC, Eber M, Methlin G. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993; 53(1): 165-169.
33. Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flesch H, Dumont P, Eber M, Abecassis J. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer 1991; 48(4): 550-556.
34. Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AK. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992; 66(6): 1188-1194.
35. Urbanski SJ, Edwards DR, Hershfield N, Huchcroft SA, Shaffer E, Sutherland L, Kossakowska AK. Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagn Mol Pathol 1993; 2(2): 81-89.
36. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 1994; 70: 506-512.
37. Pyke C, Ralfkiaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K. Localisation of messenger RNA for M, 72,000 and 92,000 type IV collagenases in human skin cancers by in-situ hybridisation. Cancer Res 1992; 52: 1336-1341.
38. Poulsom R, Hanby AM,Pignatelli M, Jeffery RE, Longcroft JM, Rogers L, Stamp GWH. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas ofthe skin. J Clin Pathol 1993; 46(5): 429-436.
39. Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffrey RE, Longeroft JM, Rogers L, Stamp GWH. Stromal expression of 72 KDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141(2): 389-396.
40. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 1990; 136(3): 585-592.
41. r 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991; 51: 439-444.
42. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limache JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699-704.
43. Okada Y, Tsuchiya H, Shimizu H, Tomita K, Nakanishi I, Sato H, Seiki M, Yamashita K, Hayakawa T. Induction and stimulation of 92-KDa gelatinase/type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumor necrosis factor a. Biochem Biophys Res Commun 1990; 171(2): 610-617.
44. Overall CM, Wrana JL, Sodek J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-β. J Biol Chem 1989; 264(3): 1860-1870.
45. Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG. Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma. J Clin Invest 1990; 86(4): 1204-1210.
46. He C, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632-2636.
47. Ito N, Nagase H. Evidence that human rheumatoid synovial matrix metalloproteinase 3 is an endogenous activator of procollagenase. Arch Biochem Biophys 1988; 267(1): 211-216.
48. Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, Yamashita K, Hayakawa T. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 1992; 267(30): 21,712-21,719.
49. Murphy G, Cockett MT, Stephens PE, Smith BJ, Docherty AJP. Stromelysin is an activator of procollagenase. Biochem J 1987; 248: 265-268.
50. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. Association between expression of activated 72-kilo-dalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85(7): 574-578.
51. Emonard HP, Remade AG, Noel AC, Grimaud JA, Stetler-Stevenson WG, Foidart JM. Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase. Cancer-Res 1992; 52(20): 5845-5848.
52. Murphy G, Willenbrock F, Ward RV, Cockett MI, Eaton D, Docherty AJ. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J 1992; 283(Pt 3): 637-641.
53. Sato H, Takino T, Kinoshita T, Seiki M. Membrane-type matrix metalloproteinase (MT-MMP) -1,-2,-3 are activator of gelatinase A/72 kDa-type IV collagenase, in Protease and Protease Inhibitors, AACR Special Conference. 1996. Marriott's Bay Point Resort, Panama City Beach, FL, p. A-52.
54. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HR. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 1988; 48: 1348,1349.
55. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F, Dano K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells or invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138(5): 1059-1067.
56. Ossowski L, Clunie G, Masucci M-T, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991; 115(4): 1107-1112.
57. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5025.
58. Sellers A, Murphy G, Meikle MC, Reynolds JJ. Rabbit bone collagenase inhibitor blocks the activity of other neutral metalloproteinases. Biochem Biophys Res Commun 1979; 87(2): 581-587.
59. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264(29): 17,374-17,378.
60. Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C. Structure and expression in breast tumours of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 1994; 54: 2091-2094.
61. Shi YE, Greene J, Wang M, Xiao G, Liu YE. Loss of expression of TIMP4, a novel human tissue inhibitor of metalloproteinase, in human breast cancer malignant progression, in Proteases and Protease Inhibitors: AACR Special Conference. 1996, Marriott's Bay Point Resort, Panama City Beach, FL, p. A-10.
62. Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981; 195: 159-165.
63. Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264(29): 17,213-17,221.
64. DeClerck YA, Yean T-D, Ratzkin BJ, Lu HS, Langley KE. Purification and characterisation of two related but distinct metalloproteinase inhibitors secreted by bovine aortic endothelialcells. J Biol Chem 1989;264(29): 17,445-17,453.
65. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He C. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci USA 1989; 86: 8207-8211.
66. Ponton A, Coulombe B, Skup D. Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res 1991; 51: 2138-2143.
67. Docherty AJP, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJR. Sequence of human tissue inhibitor of metalloproteinase and its identity to erythroid-potentiating activity. Nature 1985; 318: 66-69.
68. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992; 298(1): 29-32.
69. Welgus HG, Campbell EJ, Bar-Shavit Z, Senior RM, Teitelbaum SL. Human alveolar macrophages produce a fibroblast-like collagenase and collagenase inhibitor. J Clin Invest 1985; 76: 219-224.
70. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. J Biol Chem 1986; 261(6): 2814-2818.
71. Welgus HG, Stricklin GP. Human skin fibroblast collagenase inhibitor. J Biol Chem 1983; 258(20): 12,259-12,264.
72. Welgus HG, Jeffrey JJ, Eisen AZ, Roswit WT, Stricklin GP. Human skin fibroblast collagenase: interaction with substrate and inhibitor. Collagen Rel Res 1985; 5: 167-179.
73. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9(4): 289-303.
74. Murphy G, Reynolds JJ, Werb Z. Biosynthesis of tissue inhibitor of metalloproteinases by human fibroblasts in culture. J Biol Chem 1985; 260(5): 3079-3083.
75. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinases-2(TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990; 265(23): 13,933-13,938.
76. Tanigochi S, Iwamura T, Katsuki T. Correlation between spontaneous metastatic potential and type 1 collagenolytic activity in a human pancreatic cell line (SUIT-2) and sublines. Clin Exp Metastasis 1992; 10(4): 259-266.
77. Zucker S, Lysik RM, Wieman J, Wilkie DP, Lane B. Diversity of human pancreatic cancer cell proteinases: role of cell membrane metalloproteinases in collagenolysis and cytolysis. Cancer Res 1985; 45: 6168-6178.
78. Zucker S, Wieman JM, Lysik RM, Wilkie D, Ramamurthy NS, Golub LM, Lane B. Enrichment of collagen and gelatin degrading activities in the plasma membranes of human cancer cells. Cancer Res 1987; 47: 1608-1614.
79. Zucker S, Moll UM, Lysik RM, DiMassimo EI, Stetler-Stevenson WG, Liotta LA, Schwedes JW. Extraction of type IV collagenase/gelatinase from plasma membranes of human cancer cells. Int J Cancer 1990; 45: 1137-1142.
80. Zucker S, Moll UM, Lysik RM, DiMassimo EI, Schwedes JW, Liotta LA. Extraction of type IV collagenase/gelatinase from plasma membranes of human pancreatic cancer cells. Matrix Suppl 1992; 1:411.
81. Bramhall SR, Stamp GWH, Dunn J, Lemoine NR, Neoptolemos JP. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinase (TIMP1) in pancreatic and ampullary disease. Br J Cancer 1996; 73: 972-978.
82. Rouyer N, Wolf C, Chenard MP, Rio MC, Chambon P, Bellocq JP, Basset P. Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis 1995; 14: 269-275.
83. Saarialho-Kae UK, Crouch EC, Parks WC. Matrix metalloproteinase Matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995; 105(2): 190-196.
84. Gress TM, Mulla-Pillasch F, Lach MM, Friess H, Buchla M, Adla G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer, Int J Cancer 1995; 62: 407-413.
85. Schultz RM, Silbaman S, Pasky B, Bajkowski AS, Carmichael DF. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988; 48: 5539-5545.
86. Alvarez OA, Carmichael DF, DeClack YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 1990; 82(7): 589-595.
87. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, Denhardt DT. Antisense RNA-induced reduction in murine TIMP levels congas oncogenicity on Swiss 3T3 cells. Science 1989; 243: 947-950.
88. DeClack YA, Yean T-D, Lu HS, Ting J, Langley KE. Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2. J Biol Chem 1991; 266(6): 3893-3899.
89. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991; 83(11): 775-779.
90. Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, Oyasu R. Overexpression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma, Int J Cancer 1995; 63: 680-687.
91. DeClerck YA, Hammani K, Kohn D, Imran S. Tissue inhibitors of matrix metalloproteinases in tumor growth, in Proteases and Protease Inhibitors: AACR Special Conference. 1996. Marriott's Bay Point Resort, Panama City Beach, FL, p. 15.
92. Khokha R. Tumor development in TIMP-1 transgenic mice, in Proteases and Protease Inhibitors: AACR Special Conference. 1996. Marriott's Bay Point Resort, Panama City Beach, FL, p. 24.
93. Connolly JM, Liu X-H, Rose DP. Type IV collagenase activities in invasive human breast cancer cell lines and their regulation by linoleic acid-derived 12-hydroxyeicosatetraenoic acid (12-HETE), in Proteases and Protease Inhibitors: AACR Special Conference. 1996. Marriott's Bay Point Resort, Panama City Beach, FL, p. A-28.
94. Sledgejnr GW, Oulali M, Goulet R, Bone EA, Fife R. Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995; 87(20): 1546-1550.
95. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53(9): 2087-2091.
96. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD. Inhibition of organ invasion by the matrix metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-3633.
97. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor Batimastat (BB94). Cancer Res 1996; 56: 2815-2822.
98. Docherty AJP, Birch ML, Chander S, Cockett MI, Millican TA, Mountain A, Willmott N, Murphy G, Hart I, Mahadevan V, An Z, Huffman RM, Andason IC, Shipp MA, Teicha BA. Metalloproteinase inhibitors in the treatment of cancer, in Proteases and Protease Inhibitors: AACR Special Conference. 1996. Marriott's Bay Point Resort, Panama City Beach, FL, p. 30.
99. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R. Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87(4): 293-298.
100. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Incidence, treatment and survival in 13,560 patients with pancreatic cancer: an epidemiological study in the West Midlands. Br J Surg 1995; 82(1): 111-115.